iA Global Asset Management Inc. Purchases New Position in Illumina, Inc. $ILMN

iA Global Asset Management Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 12,393 shares of the life sciences company’s stock, valued at approximately $1,177,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Parkside Financial Bank & Trust lifted its stake in shares of Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 115 shares during the period. Quent Capital LLC purchased a new position in Illumina in the third quarter valued at $29,000. Cullen Frost Bankers Inc. acquired a new position in shares of Illumina in the second quarter worth about $41,000. NewSquare Capital LLC raised its position in shares of Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the period. Finally, Mather Group LLC. purchased a new stake in shares of Illumina during the 3rd quarter worth about $46,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the business’s stock in a transaction on Monday, November 3rd. The stock was bought at an average price of $122.13 per share, for a total transaction of $61,065.00. Following the acquisition, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on ILMN shares. Guggenheim lifted their price target on Illumina from $114.00 to $144.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Barclays raised their price objective on Illumina from $100.00 to $110.00 and gave the company an “underweight” rating in a report on Monday, December 15th. UBS Group upped their target price on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Evercore ISI reiterated an “outperform” rating and set a $155.00 target price on shares of Illumina in a research report on Monday, January 5th. Finally, Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Six equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $124.47.

Illumina Stock Performance

Shares of NASDAQ:ILMN opened at $150.28 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53. The firm has a market capitalization of $22.96 billion, a PE ratio of 33.70, a P/E/G ratio of 2.50 and a beta of 1.41. The business’s 50 day moving average price is $135.20 and its 200-day moving average price is $113.23.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 29.21% and a net margin of 16.40%.The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm posted $1.14 EPS. The firm’s revenue for the quarter was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.